Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cost of Revenue (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Cost of Revenue data on record, last reported at $66000.0 in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 57.14% year-over-year to $66000.0; the TTM value through Dec 2025 reached $146000.0, down 56.29%, while the annual FY2025 figure was $146000.0, 56.29% down from the prior year.
  • Cost of Revenue reached $66000.0 in Q4 2025 per LCTX's latest filing, up from $5000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $985000.0 in Q3 2021 and bottomed at -$494000.0 in Q4 2022.
  • Average Cost of Revenue over 5 years is $140842.1, with a median of $119000.0 recorded in 2023.
  • Peak YoY movement for Cost of Revenue: surged 865.69% in 2021, then plummeted 86.84% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $985000.0 in 2021, then tumbled by 150.15% to -$494000.0 in 2022, then skyrocketed by 151.82% to $256000.0 in 2023, then tumbled by 39.84% to $154000.0 in 2024, then crashed by 57.14% to $66000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $66000.0 in Q4 2025, $5000.0 in Q3 2025, and $39000.0 in Q2 2025.